The nation’s expert on infectious disease, Dr Anthony Fauci, confirmed on CNN on Friday that scientists at the National Institute of Allergy and Infectious Diseases are working to create a strain of coronavirus that could be used in human challenge tests of a Covid-19 fax.
© Silvio Avila / AFP / Getty Images
A nurse shows a COVID-19 vaccine produced by Chinese company Sinovac Biotech at the Sao Lucas Hospital, in Porto Alegre, southern Brazil on August 8, 2020. – The vaccine test is being conducted in Brazil in collaboration with Brazilian research institute Butanta. (Photo by SILVIO AVILA / AFP) (Photo by SILVIO AVILA / AFP via Getty Images)
In challenge studies, researchers give research studies an experimental vaccine and then intentionally expose it to coronavirus to see if the vaccine works. Since such experiments pose risks, many scientists are opposed to its use.
Fauci, director of the NIAID, described this approach as a “Plan D” – and the work is still preliminary. If necessary, trials of human challenge would be in the earliest months.
“We are taking preliminary steps,” he said, adding that a contract has been drawn up almost recently, or that it will be awarded soon, for a company to create the tension.
Fauci confirmed to CNN that a request for extension of contract had been submitted.
Fauci claims that the NIAID has no intention of using the tribe and it would only be for an “absolute far decay.”
“Honestly, I do not think this is something we will use,” Fauci said.
He added that the strain would be a “GMP” strain, which stands for “Good Production Practice.” That term is used to describe the “aspect of quality assurance that ensures that medicinal products are consistently produced and controlled to the quality standards appropriate to their intended use and as required by the product specification,” according to the World Health Organization. In the United States, current Good Manufacturing Practices are maintained as CGMP regulations by the U.S. Food and Drug Administration.
Researchers felt the need to consider this approach, so that in the highly unlikely case they would have to challenge trials, have a strain of the virus ready to use.
“It was more or less because of a lot of pressure about what happens when you don’t do it. We kept getting asked,” Fauci said.
Trials with human challenge are typically used for when a virus is not circulating widely. It is coronavirus – and therefore this approach may not be necessary, according to Fauci.
The National Institutes of Health told CNN in an email on Friday that “NIAID is currently prioritizing randomized controlled clinical trials to evaluate the safety and efficacy of SARS-CoV-2 vaccine candidates. There must be a need for human challenge studies to fully assessing candidate vaccines as therapeutics for SARS-CoV-2, NIAID has begun investigating the technical and ethical considerations of conducting studies for human challenge. “
While challenge studies deliberately expose research subjects to the virus, in randomized controlled trials, research researchers receive a vaccine as a placebo, and researchers check to see if they get sick as they go about their daily lives.
The statement also said, in part, “NIAID has begun efforts to produce a strain that could be used to develop a human challenge model, if needed, although human challenge trials would not replace the Phase 3 tears. “
Reuters reported on Friday that some drugmakers – including AstraZeneca and Johnson & Johnson – told the news service that they would consider human challenge tests to test Covid-19 vaccines as needed.
Such vaccine studies that immunize volunteers and then deliberately expose them to the coronavirus would not accelerate the development of such a shot and are still up to two years away, members of the NIH’s Accelerating Covid-19 Therapeutic Interventions and Vaccines (ACTIV) Vaccines Working Group said in July.
While some experts have speculated that trials with human challenge may be necessary, the team of fax experts who form the working group said the process would be too slow. They said that randomized, controlled vaccine tests are the most likely route to a coronavirus vaccine.
In a commentary published in the New England Journal of Medicine, ACTIV members wrote that using controlled models of human infection to support vaccine development requires “essential criteria” to limit the risk to participants and “may take one to two years.” “
“A single death as a serious illness in an otherwise healthy volunteer would be unintentional and would stop progress,” she wrote, and rescue therapy would be available because even well-established challenge studies result in unexpectedly serious illness.
Video: Can help protect against common colds against coronavirus (CNN)
Click to expand
FOLLOWING
Continue reading
